Skip to content
Sign in
StableHealthReported 2026-11-19 15:06

Evotec and Bristol Myers Squibb Receive Second IND Acceptance for Protein Degradation Partnership

Evotec and Bristol Myers Squibb received FDA IND acceptance for a second candidate in their strategic protein degradation partnership, expanding their pipeline of novel molecular glue degraders for high-value targets in oncology.

Why it matters. This achievement highlights the productivity of the collaboration and strengthens the potential for developing new therapies for unmet medical needs.

01

Evidence

  • PPR Newswire news releasesCompany2026-11-19 15:06
    its strategic protein degradation partnership with Bristol Myers Squibb has received a second Investigational New Drug (IND) acceptance
    View source